Daiichi Sankyo units file patent infringement suit against Mylan for Benicar

By Lisa Kerner

Charlotte, N.C., Aug. 2 - Daiichi Sankyo Co., Ltd. said its subsidiaries Sankyo Co., Ltd. and Daiichi Sankyo, Inc. started legal proceedings against Mylan Pharmaceuticals, Inc. and its parent company Mylan Laboratories, Inc. in the U.S. District Court for the District of New Jersey for infringement of Sankyo's U.S. patent covering olmesartan medoxomil, the active ingredient in its antihypertensive drug Benicar.

Daiichi Sankyo said the patent expires April 2016.

Mylan filed an abbreviated New Drug Application with the Food and Drug Administration to market a generic version of Benicar.

Benicar, marketed in more than 35 countries, suppresses vasoconstriction to control blood pressure.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.